292 related articles for article (PubMed ID: 24478403)
21. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M
J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068
[TBL] [Abstract][Full Text] [Related]
22. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ;
N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708
[TBL] [Abstract][Full Text] [Related]
23. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
Hentrich M; Berger M; Wyen C; Siehl J; Rockstroh JK; Müller M; Fätkenheuer G; Seidel E; Nickelsen M; Wolf T; Rieke A; Schürmann D; Schmidmaier R; Planker M; Alt J; Mosthaf F; Engert A; Arasteh K; Hoffmann C
J Clin Oncol; 2012 Nov; 30(33):4117-23. PubMed ID: 23045592
[TBL] [Abstract][Full Text] [Related]
24. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.
Carde P; Karrasch M; Fortpied C; Brice P; Khaled H; Casasnovas O; Caillot D; Gaillard I; Bologna S; Ferme C; Lugtenburg PJ; Morschhauser F; Aurer I; Coiffier B; Meyer R; Seftel M; Wolf M; Glimelius B; Sureda A; Mounier N
J Clin Oncol; 2016 Jun; 34(17):2028-36. PubMed ID: 27114593
[TBL] [Abstract][Full Text] [Related]
25. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.
Verma D; O'Brien S; Thomas D; Faderl S; Koller C; Pierce S; Kebriaei P; Garcia-Manero G; Cortes J; Kantarjian H; Ravandi F
Cancer; 2009 Jan; 115(1):101-6. PubMed ID: 19090005
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma.
Cavalieri E; Matturro A; Annechini G; De Angelis F; Frattarelli N; Gentilini F; Grapulin L; Sacco M; Torelli F; Vignetti M; Mandelli F; Foà R; Pulsoni A
Leuk Lymphoma; 2009 Nov; 50(11):1803-8. PubMed ID: 19860621
[TBL] [Abstract][Full Text] [Related]
27. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
Wheeler C; Khurshid A; Ibrahim J; Elias A; Mauch P; Ault K; Antin J
Leuk Lymphoma; 2001 Feb; 40(5-6):499-509. PubMed ID: 11426523
[TBL] [Abstract][Full Text] [Related]
28. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
Tebbi CK; London WB; Friedman D; Villaluna D; De Alarcon PA; Constine LS; Mendenhall NP; Sposto R; Chauvenet A; Schwartz CL
J Clin Oncol; 2007 Feb; 25(5):493-500. PubMed ID: 17290056
[TBL] [Abstract][Full Text] [Related]
29. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan.
Kedmi M; Apel A; Davidson T; Levi I; Dann EJ; Polliack A; Ben-Bassat I; Nagler A; Avigdor A
Acta Haematol; 2016; 135(3):156-61. PubMed ID: 26588173
[TBL] [Abstract][Full Text] [Related]
30. ABEP as primary chemotherapy for Hodgkin's disease.
Zulian GB; Mermillod B; Alberto P
Eur J Cancer; 1992; 28A(10):1727-9. PubMed ID: 1382495
[TBL] [Abstract][Full Text] [Related]
31. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
Merli F; Luminari S; Gobbi PG; Cascavilla N; Mammi C; Ilariucci F; Stelitano C; Musso M; Baldini L; Galimberti S; Angrilli F; Polimeno G; Scalzulli PR; Ferrari A; Marcheselli L; Federico M
J Clin Oncol; 2016 Apr; 34(11):1175-81. PubMed ID: 26712220
[TBL] [Abstract][Full Text] [Related]
32. [Primary refractory and relapsed Hodgkin lymphoma with unfavorable prognosis].
Tarasenkova AA; Filatova LV; Gershanovich ML; Semiglazova TIu
Vopr Onkol; 2012; 58(1):101-9. PubMed ID: 22629838
[TBL] [Abstract][Full Text] [Related]
33. Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG).
Engel C; Loeffler M; Schmitz S; Tesch H; Diehl V
Ann Oncol; 2000 Sep; 11(9):1105-14. PubMed ID: 11061603
[TBL] [Abstract][Full Text] [Related]
34. Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial.
Engert A; Josting A; Haverkamp H; Villalobos M; Lohri A; Sökler M; Zijlstra J; Sturm I; Topp MS; Rank A; Zenz T; Vogelhuber M; Nogova L; Borchmann P; Fuchs M; Flechtner HH; Diehl V
J Clin Oncol; 2010 May; 28(13):2239-45. PubMed ID: 20368566
[TBL] [Abstract][Full Text] [Related]
35. Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience.
Aguilera DG; Vaklavas C; Tsimberidou AM; Wen S; Medeiros LJ; Corey SJ
J Pediatr Hematol Oncol; 2009 Nov; 31(11):803-11. PubMed ID: 19801947
[TBL] [Abstract][Full Text] [Related]
36. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group.
Lenz G; Dreyling M; Schiegnitz E; Haferlach T; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2004 Dec; 22(24):4926-33. PubMed ID: 15611507
[TBL] [Abstract][Full Text] [Related]
37. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials.
Behringer K; Mueller H; Goergen H; Thielen I; Eibl AD; Stumpf V; Wessels C; Wiehlpütz M; Rosenbrock J; Halbsguth T; Reiners KS; Schober T; Renno JH; von Wolff M; van der Ven K; Kuehr M; Fuchs M; Diehl V; Engert A; Borchmann P
J Clin Oncol; 2013 Jan; 31(2):231-9. PubMed ID: 23150709
[TBL] [Abstract][Full Text] [Related]
38. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy.
Carney DA; Westerman DA; Tam CS; Milner A; Prince HM; Kenealy M; Wolf M; Januszewicz EH; Ritchie D; Came N; Seymour JF
Leukemia; 2010 Dec; 24(12):2056-62. PubMed ID: 20962860
[TBL] [Abstract][Full Text] [Related]
39. Osteonecrosis detected by whole body magnetic resonance in patients with Hodgkin Lymphoma treated by BEACOPP.
Albano D; Patti C; La Grutta L; Grassedonio E; Mulè A; Brancatelli G; Lagalla R; Midiri M; Galia M
Eur Radiol; 2017 May; 27(5):2129-2136. PubMed ID: 27519911
[TBL] [Abstract][Full Text] [Related]
40. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials.
Sieniawski M; Reineke T; Josting A; Nogova L; Behringer K; Halbsguth T; Fuchs M; Diehl V; Engert A
Ann Oncol; 2008 Oct; 19(10):1795-801. PubMed ID: 18544558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
